Imatinib- Mechanism of action

Imatinib has inhibitory activity against ABL and its activated derivatives v-ABL, BCR-ABL, and EVT6-ABL
Cellular studies showed that imatinib specifically inhibited the proliferation of myeloid cell lines that express the BCR-ABL fusion protein associated with CML
Similar concentrations of imatinib inhibit the proliferation of cells dependent on KIT or PDGFR for proliferation. This includes cells expressing mutant KIT isoforms associated with gastrointestinal stromal tumors (GISTs)